☆ 4.6 Meeting Abstract

Evaluation of Blood Tumor Mutation Burden for Efficacy of Second- Line Atezolizumab Treatment in Non-small Cell Lung Cancer

JOURNAL OF THORACIC ONCOLOGY (2022)

Journal

JOURNAL OF THORACIC ONCOLOGY

Volume 17, Issue 9, Pages S345-S345

Publisher

ELSEVIER SCIENCE INC

Keywords

cell-free DNA; blood tumor mutation burden; atezolizumab

Categories

Oncology Respiratory System

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.